Open AccessCurrent treatment options for colon cancer peritoneal carcinomatosis
Author(s) -
Tomoyoshi Aoyagi,
Krista P. Terracina,
Raza Ali,
Kazuaki Takabe
Publication year - 2014
Publication title -
world journal of gastroenterology
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 1.427
H-Index - 155
eISSN - 2219-2840
pISSN - 1007-9327
DOI - 10.3748/wjg.v20.i35.12493
Subject(s) - medicine , colorectal cancer , hyperthermic intraperitoneal chemotherapy , peritoneal carcinomatosis , cancer , chemotherapy , oncology , cytoreductive surgery , metastasis , peritoneal cavity , surgery , ovarian cancer
Peritoneal carcinomatosis (PC), the dissemination of cancer cells throughout the lining of the abdominal cavity, is the second most common presentation of colon cancer distant metastasis. Despite remarkable advances in cytotoxic chemotherapy and targeted therapy for colon cancer over the last 15 years, it has been repeatedly shown that these therapies remain ineffective for colon cancer PC. Recently, there has been a rapid accumulation of reports that cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) prolongs the life of colon cancer PC patients. Here, we will review the clinical presentation, the mechanisms of disease progression, and current treatment options for colon cancer PC, with a focus on the benefits and limitations of CRS-HIPEC.